Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 130 от 154

Активно (без набиране) Фаза 1

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

Начало: 12.03.2021 Край: 05.10.2027 Възраст: от 18 г. Лечение

Australia, Belgium, France +2 Janssen Research & Development, LLC NCT04722146

Активно (без набиране) Фаза 3

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Myelofibrosis

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of the study comparing the efficacy and safety of combination therapy of selinexor + ruxolitinib with combination of placebo + ruxolitinib.

Начало: 11.03.2021 Край: 01.03.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +16 Karyopharm Therapeutics Inc NCT04562389

Активно (без набиране) Фаза 2

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft-versus-host-disease

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

Начало: 04.03.2021 Край: 01.09.2027 Възраст: от 2 г. Лечение

Australia, Belgium, Canada +12 Syndax Pharmaceuticals NCT04710576

Активно (без набиране) Фаза 1

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

Начало: 04.03.2021 Край: 16.05.2026 Възраст: от 18 г. Лечение

Australia, China, New Zealand +2 BeiGene NCT04649385

Активно (без набиране)

Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients

Melanoma Skin Cancer Anxiety and Fear

This randomised controlled trial will investigate the role of melanoma surveillance photography (MSP) in the surveillance of patients at high or ultra-high risk of melanoma. MSP is a comprehensive method of melanoma monitoring which includes total body photography and digital dermoscopy which is performed at prescribed intervals. The study will test whether participants under surveillance with MSP have less unnecessary biopsies (false positives) compared to those without MSP. Participants will be Australian residents with a new diagnosis of primary melanoma, who have multiple naevi and are at high or ultra-high risk of developing melanoma. Participants will be randomised 1:1 to either groups. It is hypothesised that those randomised to surveillance with MSP will have better patient outcomes. Improved diagnostic performance as measured by the number of unnecessary biopsies will be the primary outcome measure.

Начало: 03.03.2021 Край: 01.05.2025 Възраст: от 18 г. Диагностика

Australia Melanoma and Skin Cancer Trials Limited NCT04385732

Активно (без набиране)

An Implementation Trial to Improve Access to Pulmonary Rehabilitation in People With COPD

Chronic Obstructive Pulmonary Disease

People with chronic obstructive pulmonary disease (COPD) experience distressing breathlessness and high health care utilisation. There is compelling evidence that pulmonary rehabilitation improves symptoms and reduces hospitalisation, but is delivered to \

Начало: 01.03.2021 Край: 01.02.2026 Лечение

Australia Monash University NCT04217330

Активно (без набиране) Фаза 3

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Carcinoma, Renal Cell

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

Начало: 25.02.2021 Край: 11.02.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 Merck Sharp & Dohme LLC NCT04586231

Активно (без набиране) Фаза 3

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Myeloproliferative Disorders Myelofibrosis Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis +1

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period. Following the Day 169 Response Assessment, subjects who did not show clinical benefit will have the option to unblind. Subjects who were on placebo during the Blinded Core Treatment Period will have the opportunity to crossover into the Open-Label Extension Treatment Period and receive Luspatercept.

Начало: 25.02.2021 Край: 18.08.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Celgene NCT04717414

Активно (без набиране) Фаза 1/2

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KRAS G12C Mutant Solid Tumors Carcinoma, Non-Small-Cell Lung Carcinoma, Colorectal Cancer of Lung +6

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

Начало: 24.02.2021 Край: 25.01.2027 Възраст: 18–100 г. Лечение

Australia, Belgium, Canada +12 Novartis Pharmaceuticals NCT04699188

Активно (без набиране) Фаза 3

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

Hemophilia A

Primary Objective: \- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity assays (only applicable to Arm B). * To evaluate the efficacy of BIVV001 for perioperative management

Начало: 23.02.2021 Край: 15.01.2027 Лечение

Argentina, Australia, Belgium +19 Bioverativ, a Sanofi company NCT04644575

Активно (без набиране) Фаза 3

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Metastatic Non Small Cell Lung Cancer Advanced Non Small Cell Lung Cancer

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Начало: 23.02.2021 Край: 02.07.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +18 Mirati Therapeutics Inc. NCT04685135

Активно (без набиране) Фаза 3

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.

Начало: 23.02.2021 Край: 31.03.2028 Възраст: от 18 г. Лечение

Australia, Belgium, China +9 Hoffmann-La Roche NCT04408638

Активно (без набиране) Фаза 1

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer Non Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of ABBV-637 alone or in combination with docetaxel/osimertinib in participants with solid tumors (NSCLC). Adverse events and change in disease activity will be assessed. ABBV-637 is an investigational drug being developed for the treatment of solid tumors. Study consists of 3 parts - monotherapy dose escalation (Part 1), combination dose escalation and expansion (Parts 2a and 2b) with docetaxel and combination dose escalation and expansion (Parts 3a and 3b) with osimertinib. Approximately 109 adult participants with relapsed/refractory (R/R) solid tumors will be enrolled in approximately 30 sites across the world. In Part 1, participants with solid tumors will receive intravenous (IV) ABBV-637 in 28-day cycles. In Part 2a and 2b, participants will receive IV ABBV-637 in combination with IV docetaxel in 28-day cycles. In Part 3a and 3b, participants will receive intravenous (IV) ABBV-637 in combination with daily oral tablets of osimertinib in 28-day cycle. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. Treatment effects will be monitored by medical assessments, blood tests, side effect reporting, and questionnaires.

Начало: 23.02.2021 Край: 01.02.2026 Възраст: от 18 г. Лечение

Australia, France, Israel +5 AbbVie NCT04721015

Активно (без набиране) Фаза 3

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.

Начало: 18.02.2021 Край: 01.04.2026 Възраст: от 30 г. Лечение

Australia, United States AbbVie NCT04750226

Активно (без набиране) Фаза 2

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

Начало: 17.02.2021 Край: 27.02.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +15 Bristol-Myers Squibb NCT04623775

Активно (без набиране)

Comparison of MiSight 1-Day and Acuvue Oasys for Presbyopia in Myopic Children

Myopia Progressing

This study will compare the effects on myopia progression over the course of one year for eyes wearing MiSight 1 Day contact lenses compared to ACUVUE OASYS for PRESBYOPIA contact lenses.

Начало: 11.02.2021 Край: 01.12.2025 Възраст: 6–12 г. Лечение

Australia Pauline Kang NCT06887920

Активно (без набиране)

A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA)

Friedreich Ataxia

This is a natural history study prospectively investigating neuroimaging markers of disease progression in children and adults with Friedreich ataxia (FA). There will be three assessment periods (baseline, 12 and 24 months). The study will include approximately 200 individuals with FA and 100 matched controls recruited across the six international academic sites. Other assessments will include secondary clinical and cognitive markers, as well as exploratory blood markers.

Начало: 10.02.2021 Край: 01.10.2025 Възраст: от 5 г.

Australia, Brazil, Canada +2 Monash University NCT04349514

Активно (без набиране)

Casting vs Bracing for Idiopathic Early-Onset Scoliosis

Scoliosis Idiopathic Early-Onset Scoliosis Deformity of Spine

Comparison of casting and bracing for the treatment of idiopathic early onset scoliosis

Начало: 09.02.2021 Край: 30.09.2026 Възраст: 12–36 г. Лечение

Italy, New Zealand, United States University of Iowa NCT04500041

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Severe Hemophilia A

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII \[FVIII\] level \

Начало: 04.02.2021 Край: 18.05.2030 Възраст: до 12 г. Лечение

Australia, Belgium, Brazil +10 Hoffmann-La Roche NCT04431726

Активно (без набиране) Фаза 2

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Multiple Myeloma

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Начало: 02.02.2021 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +7 Pfizer NCT04649359

1 … 128 129 130 131 132 … 154